Compare Heron Therapeutics Inc (HRTX) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.94. The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | RDTE | |
|---|---|---|
Market Cap | $63.41M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $34.20 |
52-Week Low | $0.32 | $26.40 |
Enterprise Value | $161.31M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
RDTE trades at $28.91, up 1.19% today, but technical indicators signal a bearish trend with moving averages showing significant sell pressure. The stock exhibits a consistent dividend distribution pattern, with multiple payments scheduled through mid-2026. Recent news coverage highlights the ETF's high-yield strategy but raises concerns about structural risks and capital erosion potential.
The outlook remains cautious due to the bearish technical structure and fundamental concerns about the covered-call strategy's sustainability. Investment opportunity exists for income-focused investors attracted to the dividend yield, but risks include capped upside participation and potential NAV deterioration during market rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
